Characteristics of clinical trials of new oncology drugs approved in China.

Yang, Jing; Yang, Ji; Hu, Yuan-Jia

Yang, Jing; Yang, Ji; Hu, Yuan-Jia.

Affiliation

Yang J; State Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau, Macao Special Administrative Region, China.
Yang J; School of Chinese Materia Medica, Guangdong Pharmaceutical University, Guangzhou, China.
Hu YJ; State Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau, Macao Special Administrative Region, China.

Cancer ; 130(5): 671-682, 2024 03 01.

Article in En | MEDLINE | ID: mdl-37985356

Subject(s)

Antineoplastic Agents; Humans; Antineoplastic Agents/therapeutic use; China; Clinical Trials as Topic; Drug Approval

Key words

clinical evidence; drug lag; novel anticancer drugs; pivotal clinical trials; programmed death-1 (PD-1) inhibitors; programmed death-ligand 1 (PD-L1) inhibitors

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Database: MEDLINE Main subject: Antineoplastic Agents Limits: Humans Country/Region as subject: Asia Language: En Year: 2024 Type: Article

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Database: MEDLINE Main subject: Antineoplastic Agents Limits: Humans Country/Region as subject: Asia Language: En Year: 2024 Type: Article